|
LYEL Lyell Immunopharma Inc 1806952 |
| Balance Sheet |
|
Current Assets
|
$213,541,000.00 |
|
Assets
|
$311,153,000.00 |
|
Current Liabilities
|
$39,867,000.00 |
|
Liabilities
|
$77,338,000.00 |
|
Equity
|
$233,815,000.00 |
|
Shares Out
|
23396808.00 |
| Cash Flow Statement |
|
Operating Cash Flow
|
$-72,432,000.00 |
|
Investing Cash Flow
|
$32,994,000.00 |
| Market Analysis |
Market Cap
|
$359,141,002.80 |
|
Price
|
$11.01 |
|
BVPS
|
9.99 |
|
PB
|
1.54 |
|
EPS
|
-1.92 |
|
PS
|
22446.31 |
|
FCF
|
$-72,777,000.00 |
|
| Dividends |
|
Dividend Data Last Updated
|
2026-09-01 09:32:44 |
|
|
| Earnings |
|
Earnings Last Updated
|
2026-09-14 10:01:35 |
|
| Apr |
May |
Jun |
| 2026-03-12 |
|
|
|
2026-05-06 |
-1.10 |
|
|
Find a discrepancy? The most accurate way to find company fundamental data is to view LYEL documents filed with the SEC.
LYEL Filings
Clear
